Success for AstraZeneca lung cancer therapy 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1 

Context 

Lung cancer accounts for a quarter of all cancer deaths in Scotland, with NSCLC being the most common form of the disease.2 Almost half of lung cancers (47%) in Scotland are diagnosed at a late stage (Stage IV), when the cancer has spread to other parts of the body.3 AstraZeneca estimates that approximately 192 patients in Scotland with locally advanced or metastatic EGFRm NSCLC will be eligible for targeted therapy with osimertinib every year. 

Trial results 

Results from the FLAURA Phase III trial showed a statistically significant and clinically meaningful improvement in median overall survival (OS) in patients treated with osimertinib, versus gefitinib or erlotinib, both of which were previous standard-of-care (SoC) treatments in this setting (38.6 versus 31.8 months; Hazard Ratio [HR] 0.799 [95% CI, 0.641-0.996], p=0.0462).2,4 

Osimertinib also showed a statistically significant and clinically meaningful 52% reduction in the risk of central nervous system (CNS) disease progression at 18 months, increasing the time patients with CNS metastases lived without CNS disease progression or death (HR 0.48 [95% CI, 0.26-0.86], p=0.014).2,5 As patients with CNS lesions typically have poor outcomes, a reduction in CNS disease progression could potentially lead to an enhanced quality of life.5 

Official comments 

Tom Keith-Roach, President, AstraZeneca UK, said: “This decision from the SMC is further welcome news aligned with the Scottish Government’s commitment to cancer as a national clinical priority. Providing access to cutting-edge treatments like osimertinib is an important part of getting back on track post-Covid.” 

Arun Krishna, Head of Oncology, AstraZeneca UK, said: “With almost half of all lung cancers in Scotland diagnosed at a late stage, there is a clear unmet need for additional effective treatment options. Osimertinib can significantly increase survival of patients with EGFR mutation-positive NSCLC, with a comparable safety profile to first generation EGFR TKIs. It’s fantastic news that patients in Scotland now have access to this product of British science.” 

References 

  1. Scottish Medicines Consortium. Osimertinib 40mg and 80mg film-coated tablet (Tagrisso®). SMC2382. Published 17 January 2022.
  2. Cancer in Scotland Summary. April 2019. NHS National Services Scotland. Available at: https://www.isdscotland.org/Health-Topics/Cancer/Publications/2019-04-30/Cancer_in_Scotland_summary_m.pdf. Last accessed: January 2022.
  3. Public Health Scotland. Cancer Incidence and Prevalence in Scotland (to December 2019). Published: 11 May 2021. Available at: https://publichealthscotland.scot/media/7753/2021-05-11-cancer-incidence-report.pdf. Last accessed: January 2022.
  4. Tagrisso(osimertinib). Summary of Product Characteristics. 6 May 2021. Available at: https://www.medicines.org.uk/emc/product/1985/smpc#gref. Last accessed: January 2022. 
  5. Liu HM, Meng CL, Zhao LJ.Survival Outcomes of Local Compared With Systemic First Treatment of Non-Small Cell Lung Cancer Brain Metastases. Front Oncol. 2021;11:4598. 

 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free